Welcome to our dedicated page for Biomx news (Ticker: PHGE), a resource for investors and traders seeking the latest updates and insights on Biomx stock.
BiomX Inc. (PHGE) news is centered on the company’s transition from a legacy phage therapy profile toward defense, security, critical infrastructure, and first-response technologies. Recent company announcements focus heavily on Zorronet, an AI defense technology subsidiary that develops command-and-control, computer vision, and autonomous surveillance systems.
PHGE news can include acquisition updates, material agreements, customer deployments, and operating details tied to Zorronet and DFSL. Zorronet-related coverage has included AI command-and-control software, secure on-premise and hybrid C5ISR deployments, mobile field-operator tools, and the use of cameras, sensors, drones, and IoT devices in integrated security environments.
Infrastructure and government-related items are also important for BiomX coverage. Company disclosures have discussed Zorronet’s work with Israel Railways, contracts with the Israel Defense Forces, and engagements involving government customers, Tier-1 OEMs such as Elbit Systems, and international clients. DFSL adds another news angle through LADAR-based detection systems for perimeter security, critical infrastructure, and counter-UAS markets.
BiomX news may also include SEC filing events, shareholder votes, governance changes, capital-structure disclosures, and operating results. Because the company has disclosed substantial doubt about its ability to continue as a going concern, financing and liquidity-related disclosures are also material to PHGE coverage. For investors tracking PHGE, the main news themes are defense technology acquisitions, operational deployments, critical infrastructure agreements, and the company’s remaining phage therapy background.
BiomX (NYSE American: PHGE), a clinical-stage firm developing phage therapies, will present data from its Phase 1b/2a trial of BX004 for cystic fibrosis patients with chronic Pseudomonas aeruginosa infections. These findings will be shared at the 47th European Cystic Fibrosis Conference (June 5-8, 2024, Glasgow) and ASM Microbe 2024 (June 13-17, 2024, Atlanta). Key presentations include an oral session and ePoster at the European conference, and a Rapid Fire session and poster at ASM Microbe. The presentations will be accessible on BiomX's website on June 6 and June 17, respectively.
BiomX, a clinical-stage company advancing phage therapies, has reported its Q1 2024 financial results and provided updates on its programs.
Following its merger with Adaptive Phage Therapeutics in March 2024 and a $50 million private placement, BiomX has a cash balance of $44.1 million, providing a runway through Q4 2025.
Key clinical programs include BX211 for diabetic foot osteomyelitis, expecting Phase 2 results in Q1 2025, and BX004 for cystic fibrosis, with Phase 2b results anticipated in Q3 2025. Financially, net loss increased to $17.3 million, primarily due to changes in warrant values and merger-related expenses.
R&D expenses decreased to $4.1 million while G&A expenses rose to $2.7 million.
BiomX (NYSE American: PHGE), a clinical-stage company specializing in phage therapies targeting pathogenic bacteria, announced a conference call and webcast scheduled for May 21, 2024, at 8:00 a.m. ET.
The event will cover the company's first quarter 2024 financial results along with business and program updates. Participants can join the call via dedicated U.S. and international dial-in numbers, and the webcast will be accessible in the Investors section of BiomX's website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.